Kornimate/medical-research-clean huggingface dataset:
bacteriotherapy to improve underarm odor

Conditions: Bromhidrosis

Summary: the goal is to improve the underarm odor by changing the microbiome. the autochthonous bacterial community is replaced by a non-smelling microbiome, by daily application of bacteria in a spray.

participants are recruited and selected based on their initial underarm odor and underarm microbiome. the participants use two sprays: one spray containing the bacteria, and the other nothing (placebo). participants do not know which spray they have. they use one spray during one month, and meanwhile take samples of their underarm microbiome (for sequencing), volatome (for gc/ms analysis) and odor (for odor panel analysis). samples are stored in the freezer and brought to the university after one month, when they receive the second spray. the bacterial spray contains bacteria that are correlated with good underarm odor.

Eligibility criteria:
inclusion criteria: * above average underarm malodor * microbiome dominated with malodorous bacteria exclusion criteria: * not healthy * microbiome with too high levels of staphylococcus
initial treatment for acute bacterial skin infections (absssi) caused by staphylococcus aureus

Conditions: Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA); (Susceptible or Methicillin Resistant)

Summary: the study investigates the safety and efficacy of pmx-30063 in patients treated for acute bacterial skin and skin-structure infection (absssi).


Eligibility criteria:
inclusion criteria: 1. have a diagnosis of absssi in which s. aureus is clinically suspected to be the likely pathogen 2. clinical manifestation of subjects' absssi must include the presence of purulent material suitable for microbiologic culture, gram stain examination and pcr assay. 3. the absssi must be 75 cm2 or greater in size in order for the subject to be eligible for this study. this includes the primary and surrounding erythema, swelling or induration. 4. super-infected eczema or other chronic medical conditions (e.g., atopic dermatitis, hidradentitis suppurativa) characterized by prominent signs of inflammation for an extended period even after successful bacterial eradication. (subjects with an absssi that involves an anatomic location in which there is no evidence of a chronic skin condition are eligible for enrollment.) exclusion criteria: 1. female patients who are pregnant, lactating (breast milk feeding), or planning a pregnancy during the course of the study. 2. history of peripheral neuropathy of any form or etiology 3. anticipated need for prolonged antibiotic therapy (i.e., \>8 days) 4. absssi known or suspected to be caused exclusively by gram negative pathogens or anaerobes (both gram positive or gram negative) 5. diabetic foot infection: defined as a subacute or chronic infection (\> 4 weeks) below the ankle in a patient with diabetic neuropathy 6. infected burns 7. known infection with human immunodeficiency virus (hiv) and a cd4 count \< 200/mm3 8. active hepatitis b or hepatitis c receiving treatment with interferon or other immunosuppressive therapy

Keywords: mrsa absssi staphylococcus aureus
ultrastructural changes of trabeculectomy specimens in patients with uveitic secondary glaucoma

Conditions: Uveitis; Secondary Glaucoma

Summary: ultrastructural analysis of trabeculectomy specimens of patients with uveitic secondary glaucoma. to evaluate morphological changes and to compare to primary open angle glaucoma patients.


Eligibility criteria:
inclusion criteria: * secondary uveitic glaucoma * iop \> 24 mmhg with topical and/or systemic therapy * need for surgical intervention to control iop

Keywords: trabecular meshwork electron microscopy
gat-dct-discordance due to corneal properties

Conditions: Glaucoma

Summary: iop is measured with two devices (dynamic contour tonometry (dct) and goldmann applanation tonometry (gat)).

dct reading will be compared to a corrected gat reading by the formula of elsheikh, alhasso and pye. * trial with medical device

Eligibility criteria:
inclusion criteria: * clinical diagnosis of glaucoma exclusion criteria: * other optic neuropathy other then glaucoma * age\<18 * corneal surgery * use of contact lenses

Keywords: glaucoma goldmann tonometry dynamic contour tonometry
efficacy of docetaxel, capecitabine, cisplatin, and bevacizumab in patients with unresectable advanced gastric cancer

Conditions: Advanced Gastric Cancer

Summary: the purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and bevacizumab are effective in the treatment of unresectable advanced gastric cancer.

in our previous phase ii study of neoadjuvant docetaxel, capecitabine and cisplatin chemotherapy, patients with unresectable gastric cancer because of invasion to adjacent organs or metastasis to para-aortic lymph nodes received benefit from neoadjuvant chemotherapy. based on these results and reports that bevacizumab enhances response rate, we planned docetaxel, capecitabine, cisplatin, and bevacizumab as neoadjuvant chemotherapy for patients with local invasion or para-aortic node metastasis alone.

Eligibility criteria:
inclusion criteria: * histologically documented adenocarcinoma of the stomach or gastroesophageal junction. * invasion to adjacent organ (t4) proven by endoscopic ultrasonography (eus) or presence of paraaortic lymph node metastasis by ct and pet(short-axis diameter \> 1 cm showing hot uptake in pet scan). * age 18-70 years old * ecog performance status 0-2 * adequate hepatic function(serum bilirubin \<1.5mg/dl, ast (sgot) and alt (sgpt) \< 2.5 x unl, alkaline phosphatase \< 5 x unl) * adequate renal function(serum creatinine \<1.5mg/dl) * adequate bone marrow function (wbc ≥4000 cell/㎕ with anc ≥1500 cell/㎕, platelet count ≥100,000 cell/㎕) * her2 negative (her2 immunohistochemistry 0 or 1+, immunohistochemistry 2+ but fish negative) * informed consent exclusion criteria: * other histologic type than adenocarcinoma * metastasis in other sites than paraaortic lymph nodes, like in liver or peritoneum. * presence or history of other cancers * history of prior chemotherapy, antiangiogenic agents, or radiation. * patients with definite ascites in abdomen ct scan * presence of not adequately controlled cns metastasis * bowel obstruction * evidence of gastrointestinal bleeding * other serious illness or medical conditions including hypertension uncontrolled by medication. * pregnant or lactating women

Keywords: advanced gastric cancer neoadjuvant bevacizumab
reducing antiretroviral treatments

Conditions: HIV-1-infection

Summary: the purpose of this trial is to demonstrate at w48 the non-inferiority of a dual nucleoside analogues strategy with tenofovir (tdf) or tenofovir alafenamide (taf) plus emtricitabine (ftc) or lamivudine (3tc) preceded by a 16 week induction period with tdf or taf plus ftc or 3tc plus an integrase inhibitor (ini) relative to an immediate 2-dr strategy with dolutegravir plus 3tc in hiv-infected antiretroviral therapy (arv) naïve participants with cd4 cells count greater than 300/mm3 and a low viral load defined as plasma hiv rna strictly lower than 50 000 cp/ml

anrs 173 altar is a multicenter, comparative, international, open label, phase iii randomized trial aiming at evaluating the non-inferiority of a tri-bi (tritherapy-bitherapy) strategy (includes a 16 week - induction phase with 2 nrti and a once daily integrase inhibitor followed by a bitherapy with tdf or taf / xtc\*) in its capacity to achieve viral suppression at week 48 versus immediate bi (bitherapy) strategy (dtg/3tc) in participants naïve to antiretroviral therapy with plasma hiv rna strictly less than 50 000 copies/ml and cd4 cells count above 300/mm3.

Eligibility criteria:
inclusion criteria: * documented hiv-1 infection (positive hiv-1 serology or plasma viral load) * age ≥ 18 years * therapeutic antiretroviral treatment-naive participant (history of prophylaxy is accepted) * cd4 cells count \> 300 cells/mm3 at screening visit * hiv-1-rna plasma viral load \<50 000 copies/ml at screening visit * full susceptibility to trial drugs (nrti, ini) at screening visit * egfr (epidermal growth factor receptor) \> 60 ml /min (mdrd) * ast (aspartate aminotransferase), alt(alanine transaminase) \< 3x norm * absence of any aids-defining event and/or opportunistic infection * possible contact by phone and/or email in order to be informed in case of detectable hiv plasma viral load * negative urinary pregnancy test at screening visit for women of childbearing age * written and informed consent signed * for french participants only: subject enrolled in or a beneficiary of a social security programme (including state medical aid (ame), only if ethic committee approves it) exclusion criteria: * hiv-2 co-infection * hepatitis b virus infection (positive hbs antigen) * any comorbidity potentially related to a life expectancy below 12 months * any condition (use of alcohol, drugs, etc.) judged by the investigator to possibly interfere with trial protocol compliance, adherence and/or trial treatment tolerance * pregnant women or breastfeeding women * women of childbearing age that do not want to use an effective method of contraception * participant under justice protection * galactose/lactose intolerance, lapp lactase deficiency or glucose/galactose malabsorption (known or documented) * participation to another clinical trial evaluating a new treatment/therapy
safety, tolerability, pharmacokinetics and efficacy of yhd1044

Conditions: Premature Ejaculation

Summary: safety and tolerability, pharmacokinetics/efficacy of an escalating, repeat doses of yhd1044 in premature ejaculation


Eligibility criteria:
inclusion criteria: * patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study * history of premature ejaculation in the 6 months before study initiation * history of intravaginal ejaculatory latency time (ielt) of \< = 2 minutes in at least half of events * premature ejaculation diagnostic tool (pedt) \> =11 * 6 domains of international index of erectile function(iief) \>= 21 * patient and partner must agree to attempt sexual intercourse at minimum intervals specified in the protocol * patient's partner must have a negative urine pregnancy test at time of screening exclusion criteria: * medical history which affects adme in the past 3 years * clinically significant and active disorder in ophthalmic system, gastro-intestine, cardiovascular, respiratory system, endocrine system, autoimmune system or malignant tumor, * subjects with clinically significant observations considered as unsuitable based on medical judgment in the physical examination and clinical laboratory tests or a medical history * history of psychological disease * clinically significant allergic disease * hypersensitivity to tca, ssris(clomipramine, sertraline, fluoxetine, dapoxetine) * taken dapoxetine within 3 months * using other forms of therapy for treatment of pe (behavioral therapy or medications applied to the skin) * taken another investigational drug within 1 month * history of drug abuse
geriatric evaluation to predict mortality and functional recovery after trans aortic valve implantation

Conditions: Symptomatic Aortic Stenosis

Summary: transcutaneous trans-aortic valve replacement (tavr) is now a common procedure to treat symptomatic aortic stenosis. although as effective and safe as surgical aortic valve replacement, it is still restricted to high surgical risk patient who are frail. the aim of the tavi-eva is to identify geriatric biomarkers that may help to predict survival and functional recovery after tavr

primary objective: identify geriatric biomarkers associated with vital/functional status after tavr. primary outcome measure is altered functional status at six month follow-up defined as an absolute decrease of 15 points of the barthel index. secondary outcome measures are: barthel index and survival at 6, 9 and 12 months follow-up. qol during follow-up

Eligibility criteria:
inclusion criteria: * age ≥75 * symptomatic aortic stenosis * prior geriatric evaluation * patient who agreed to answer the telephone follow-up to 6, 9 and 12 months * patient given his non-opposition to using his data * patient affiliated to the french social security. exclusion criteria:

Keywords: aortic stenosis tavr frailty elderly
needle-based percutaneous ablation of liver tumors.

Conditions: Liver Tumors; HCC - Hepatocellular Carcinoma; Metastatic Liver Tumor

Summary: the goal of this clinical trial is to learn if int001 can ablate liver tumors in adults in an outpatient setting. it will also help us learn about the safety of int001. the main questions it aims to answer are: 1. using a needle under image guidance, the liver tumor is accessed and int001 is injected. upon injection into tumor, does int001 ablate/kill the tumor entirely? 2. what medical problems do participants experience when receiving int001? participants will: receive int001 on day 1. visit the clinic day 7, 30 and 90. receive lab tests during each visit and mri on day 30 and 90.


Eligibility criteria:
inclusion criteria: 1. diagnosis of primary or secondary liver cancer. 2. ecog performance status score of 0 - 2 3. age ≥18 years, \<100 years 4. life expectancy of ≥3 months 5. patient is unsuitable for surgical resection or transplantation 6. ability of the patient to understand and sign the informed consent form describing the study's nature 7. volunteer's willingness and ability to comply with protocol requirements, including all procedures, clinical evaluations, and follow-up visits exclusion criteria: 1. decompensated liver function, specifically child-pugh c, moderate to severe ascites, coagulopathy, or severe cirrhosis. 2. signs of liver dysfunction: ast or alt \>5 times the upper limit of normal (uln), serum bilirubin level \>2.0 mg/dl 3. individuals with bleeding disorders. 4. history of allergy or intolerance to contrast agents to be used during imaging for assessing treatment efficacy after int001 application. 5. patients with life-threatening serious extrahepatic disease. 6. patients with concurrent conditions that, in the investigator's opinion, would prevent clinical benefit from the study procedure or could compromise patient safety or study objectives (including but not limited to ongoing infection, renal dysfunction, or morbidity). 7. significant medical or psychiatric illness. 8. pregnant or breastfeeding women or women planning to conceive within the next 6 months. 9. patients participating in another study investigating a device, drug, or procedure that may impact the study treatment outcome. 10. lesions that do not show contrast uptake on contrast-enhanced ct or mr angiography. 11. lesions that are not hypervascular on angiography. 12. patients who do not have ct or mr imaging available at the screening visit or are unwilling or unable to undergo mri for various reasons during the study.

Keywords: liver tumor ablation needle out-patient
children with hiv and asthma (chivas)

Conditions: T Cell Response to Asthma in HIV-infected Patients Before and After Starting Treatment

Summary: to explore allergen-specific effector and regulatory t cell response in hiv-infected children before and after haart initiation

recently, us investigators have observed that hiv-infected (hiv+) children on highly active antiretroviral therapy (haart) have a much greater cumulative incidence of asthma.regulatory t cells may mitigate the pathogenicity of asthma through the suppression of th2 responses. since asthma is predominantly a th2 mediated condition, we propose that new onset of asthma after haart in hiv- infected children may be secondary to dysregulated immune reconstitution. the restoration of cd4+ t cell-mediated immunity in hiv+ patients treated with haart may lead to airway inflammation, narrowing, hyperresponsiveness, and possibly remodeling. the increased incidence of asthma in hiv-infected children treated with haart is likely secondary to multiple factors that may include hypersensitivity to certain aeroallergens, dysregulation of effector and regulatory t cell response, as well as the imbalance of th1 vs. th2 cytokines. therefore this study will identify the immunopathogenesis of increased airway hyperresponsiveness in hiv-positive patients.

Eligibility criteria:
inclusion criteria: 1. children aged 2-18 years 2. parent signed inform consent and children signed assent form 3. children who are starting highly active antiretroviral therapy (haart) due to clinical indication or switching haart due to treatment failure within 45 days after screening visit exclusion criteria: 1. pregnancy 2. history of chronic lung disease including lymphoid interstitial pneumonitis (lip), and bronchopulmonary dysplasia (bpd). 3. active opportunistic infections i.e. pulmonary tuberculosis, pcp, pneumonia 4. conditions limiting ability of subject to comprehend questionnaires (i.e. mental retardation).

Keywords: hiv-infected children t cell response asthma
cohort event monitoring study of pyramax®

Conditions: Malaria,Falciparum

Summary: the study is to be performed in public health facilities in central and west africa where pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes. the study is to assess the safety of pyramax, particularly in patients with underlying liver function abnormalities, in patients who have co-morbid conditions, such as hiv, and also in very small children (\<1 year of age).

this is a non-comparative cohort event monitoring study. the study will assess the safety of pyramax in terms of the evaluation and identification of the hepatic safety events in a sub group of patients enrolled with liver function tests (lft)s \>2x upper limit of normal (uln) from blood taken immediately prior to treatment without any clinical signs or symptoms of hepatotoxicity and with signs and symptoms of uncomplicated malaria confirmed by a rapid diagnostic test (rdt) or microscopy (thick blood smear). the study will compare the clinical hepatic safety of pyramax between a cohort of patients enrolled with lfts \>2xuln and a cohort of patients enrolled with normal lfts matched for demographic characteristics. an estimated 8,572 malaria episodes are to be recruited to provide 120 malaria episodes in patients with baseline raised lfts \>2xuln for follow up of liver function. a cohort of at least 2% of children who are \<1 year of age will be included for monitoring of liver function.

Eligibility criteria:
inclusion criteria: * uncomplicated malaria (plasmodia of any species) diagnosed as per national policies and in line with who recommendations: * fever or history of fever in the previous 24 h and/or the presence of anaemia, for which pallor of the palms appears to be the most reliable sign in young children. * confirmation of malaria by a parasitological diagnosis (rdt or microscopy (thick blood smear). analysis). * weight ≥5 kg - \< 20 kg (granules); ≥20 kg (tablets). * ability to take an oral medication. * ability and willingness to participate based on signed informed consent (a parent or a guardian has to sign for children below 18 years old) and on signed assent form for minors that could be required per national regulations in each participating country. * the patient has to comply with all scheduled follow-up visits. exclusion criteria: * patients with clinical signs or symptoms of hepatic injury (such as nausea, abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, child-pugh stage 3 or 4). * known allergy to artemisinin and/or to pyronaridine. * known pregnancy. * lactating women should be excluded if other anti-malarial treatments are available. * complicated malaria as per who definition (annex 2) * patients that the investigator considers would be at particular risk if receiving an anti-malarial or if participating in the study. * patients having been treated with pyramax in the previous 28 days.

Keywords: uncomplicated malaria pyramax pyronaridine artesunate
two-layer suturing of achilles tendon ruptures

Conditions: Achilles Tendon Rupture

Summary: the purpose of the present study is to measure whether a new technique of double row suturing of a ruptured achilles tendon will result in a normalization of the length of the soleus part (primary outcome) and of the superficial gastrocnemius part of the tendon (secondary outcome) one-week post-operative. results will be compared to that of a participants group that underwent the same operation but with a standard operative technique and the same rehabilitation regime recently completed (nct04263493). the investigators hypothesize that the new suturing technique will result in an elongation of the soleus part of the achilles tendon (primary outcome) by 8.9 mm or less relative to the uninjured contralateral side one week (primary endpoint) after surgery compared to retrospective data from a recently completed randomized controlled trial

this study is an ambidirectional cohort study with a retrospective part based on a recently completed trial (nct04263493) and this prospective registered trial.

Eligibility criteria:
inclusion criteria: * diagnosed with a traumatic, complete mid-substance achilles tendon rupture * manages transportation to/from the hospital on their own * presented within 14 days from injury * adult (18 to 60 years) * understands danish exclusion criteria: * other injuries affecting their lower limb functions * prior achilles contralateral tendon rupture * contraindications for mri * re-rupture * smoking * systemic diseases influencing tendon healing * anticoagulation treatment * inability to follow rehabilitation or complete follow-ups * immunosuppressive treatment including systemic corticosteroid treatment.
cldn18.2 targeting pet imaging in patients with gastrointestinal tumors

Conditions: Gastrointestinal Cancer

Summary: the objective of the study is to constrcut a noninvasive approach 124i-18b10(10l) pet/ct to detect the cldn18.2 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from cldn18.2 targeting treatment.


Eligibility criteria:
inclusion criteria: * 1. aged \>18 years old; ecog 0 or 1; * 2. patients with gastrointestinal tumors; * 3. has at least one measurable target lesion according to response evaluation criteria in solid tumors (recist v1.1); * 4. life expectancy \>=12 weeks. exclusion criteria: * 1. significant hepatic or renal dysfunction; * 2. is pregnant or ready to pregnant; * 3. cannot keep their states for half an hour; * 4. refusal to join the clinical study; * 5. suffering from claustrophobia or other mental diseases; * 6. any other situation that researchers think it is not suitable to participate in the experiment.